Nuvectis Pharma, Inc.

The momentum for this stock is not very good. Nuvectis Pharma, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Nuvectis Pharma, Inc..

News

Nuvectis Pharma (NASDAQ:NVCT) Trading Down 8.5%

Zolmax Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) traded down 8.5% on Tuesday . The stock traded as low as $6.14 and last traded at $6.27. 62,181 shares changed hands during trading, a decline of...\n more…

Insider Buyers Lose Additional US$46k As Nuvectis Pharma Dips To US$115m

Simply Wall St Insiders who acquired US$142.2k worth of Nuvectis Pharma, Inc.'s ( NASDAQ:NVCT ) stock at an average price of US$9.18...\n more…

Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...\n more…

Nuvectis Pharma announces U.S. FDA granted ODD for NXP800

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Globe Newswire FORT LEE, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ( Nuvectis or the Company ), a clinical-stage biopharmaceutical company focused on the development of...\n more…